DocWire News Editors

DocwireNews

Canagliflozin lowered cardiovascular events, and kidney failure, in patients with <a href="https://www.docwirenews.com/docwire-pick/home-page-picks/diabetes-improved-physical-activity/">type 2 diabetes</a> mellitus, according to a <a href="https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.119.042007">new paper</a> in Circulation.According to <a href="https://clinicaltrials.gov/ct2/show/NCT02065791?term=NCT02065791&amp;rank=1">ClincalTrials.gov</a>, the purpose of the&nbsp; Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants with Diabetic Nephropathy (<a href="https://www.ncbi.nlm.nih.gov/pubmed/31291786?dopt=Abstract">CREDENCE</a>) was to assess the effects of canaglifozin on both renal and cardiovascular outcomes in type 2 diabetics with diabetic nephropathy.&ldquo;Canagliflozin reduces the risk of kidney failure in patients with type 2 diabetes and chronic kidney disease, but effects on specific cardiovascular outcomes are uncertain, as are effects in people without prior cardiovascular disease (primary prevention),&rdquo; the researchers wrote in their abstract.The researchers looked at 4,401 participants with type 2 diabetes plus chronic kidney disease. Participants were randomized (1:1) to either canagliflozin or placebo with standard care. The primary outcome of interest was the time to first occurrence of an event of the composite endpoint of end-stage kidney disease, doubling of serum creatinine, renal, or cardiovascular death. There were multiple secondary endpoints, including, time to first occurrence of an even in the composite of CV death and hospitalized congestive heart failure; time to first occurrence of an endpoint event in the composite of cardiovascular death, nonfatal myocardial infarction, and others. Primary prevention participants (n=2,181; 49.6%) tended to be younger, more often female, and had a shorter duration of diabetes compared with the secondary prevention groups (n=2,220; 50.4%).The results showed that canagliflozin lowered the risk for major cardiovascular events overall (HR=0.80; 95% CI, 0.67 to 0.95; P=0.01) in both the primary prevention and secondary prevention groups. These effects were consistent across components of the composite endpoint, including cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke. The risk for the composite renal outcome was reduced, along with the risk of the cardiovascular death or hospitalization or heart failure composite outcome.&ldquo;Canagliflozin significantly reduced major cardiovascular events, as well as <a href="https://www.docwirenews.com/docwire-pick/may-2019-kidney-abstract-roundup/">kidney</a> failure, in patients with type 2 diabetes and chronic kidney disease, including in participants who did not have prior cardiovascular disease,&rdquo; the researchers concluded.<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
More data..primary prevention of CVD..Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results from the Randomized CREDENCE Trial| &#8294;<a href="https://twitter.com/CircAHA?ref_src=twsrc%5Etfw">@CircAHA</a>&#8297; <a href="https://t.co/Cdi5ze0x7u">https://t.co/Cdi5ze0x7u</a>
&mdash; TEJAS PATEL MD, FACP, FASN (@GenNextMD) <a href="https://twitter.com/GenNextMD/status/1149662230293569543?ref_src=twsrc%5Etfw">July 12, 2019</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script><blockquote class="twitter-tweet" data-width="500" data-dnt="true">
<a href="https://t.co/B3ckn3BjwA">https://t.co/B3ckn3BjwA</a> Canagliflozin significantly reduced major CVD events, as well as kidney failure, in patients with T2D and chronic kidney disease, including in participants who did not have prior CVD. <a href="https://twitter.com/hashtag/CREDENCE?src=hash&amp;ref_src=twsrc%5Etfw">#CREDENCE</a> <a href="https://twitter.com/hashtag/kidneyInCVD?src=hash&amp;ref_src=twsrc%5Etfw">#kidneyInCVD</a> <a href="https://twitter.com/AHAScience?ref_src=twsrc%5Etfw">@AHAScience</a> <a href="https://twitter.com/NephJC?ref_src=twsrc%5Etfw">@nephJC</a> <a href="https://t.co/wLXOr0DCzJ">pic.twitter.com/wLXOr0DCzJ</a>
&mdash; Kidney in Cardiovascular Disease (@KidneyInCVD) <a href="https://twitter.com/KidneyInCVD/status/1150490803564929024?ref_src=twsrc%5Etfw">July 14, 2019</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script><blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results from the Randomized CREDENCE Trial | Circulation <a href="https://t.co/hgNNHG0NpE">https://t.co/hgNNHG0NpE</a>&nbsp;&hellip; <a href="https://t.co/t2uCSw2c5h">https://t.co/t2uCSw2c5h</a> <a href="https://t.co/ktr3hP46tZ">pic.twitter.com/ktr3hP46tZ</a>
&mdash; Foroactua (@Foroactua) <a href="https://twitter.com/Foroactua/status/1149947729503608832?ref_src=twsrc%5Etfw">July 13, 2019</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script><blockquote class="twitter-tweet" data-width="500" data-dnt="true">
<a href="https://t.co/7AyNFrwAYE">https://t.co/7AyNFrwAYE</a> <a href="https://twitter.com/AntonioJordanR?ref_src=twsrc%5Etfw">@AntonioJordanR</a> @Blanchoblanchet <a href="https://twitter.com/ESC_Journals?ref_src=twsrc%5Etfw">@ESC_Journals</a> <a href="https://twitter.com/onco_cardiology?ref_src=twsrc%5Etfw">@onco_cardiology</a> <a href="https://twitter.com/endo_german?ref_src=twsrc%5Etfw">@endo_german</a> <a href="https://twitter.com/IncichR?ref_src=twsrc%5Etfw">@IncichR</a> <a href="https://twitter.com/carlos_sierra?ref_src=twsrc%5Etfw">@carlos_sierra</a> <a href="https://twitter.com/krychtiukmd?ref_src=twsrc%5Etfw">@krychtiukmd</a> <a href="https://twitter.com/neuroecheverria?ref_src=twsrc%5Etfw">@neuroecheverria</a> <a href="https://twitter.com/Dany9_RD?ref_src=twsrc%5Etfw">@Dany9_RD</a> <a href="https://twitter.com/smexcardiologia?ref_src=twsrc%5Etfw">@smexcardiologia</a> <a href="https://twitter.com/cardiodata?ref_src=twsrc%5Etfw">@cardiodata</a>
&mdash; Diego Araiza MD (@drdargaray) <a href="https://twitter.com/drdargaray/status/1150406420321447937?ref_src=twsrc%5Etfw">July 14, 2019</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>&nbsp;

Kathleen Liu, MD

Joel M. Topf, MD, FACP

AKI Approaches and ASN Kidney Health Guidance

NKF Spring Clinical Meetings 2025

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

2025 Hume Award Winner Is Dedicated to Children’s Care

Latest News

Canagliflozin Lowers Cardiovascular Risks in Type 2 Diabetics

Nephrology Times

Canagliflozin lowered cardiovascular events, and kidney failure, in patients with type 2 diabetes mellitus, according to a new paper in Circulation.
 ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe